Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of 9MW2821 versus investigator's choice chemotherapy in previously treated advanced or metastatic triple-negative breast cancer
CTR20261518Phase 3Active
- Sponsor
- Mabwell
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bulumtatug fuvedotin in triple-negative breast cancer (TNBC), sponsored by Mabwell. Started May 2026; status: active.
02
Drugs
bulumtatug fuvedotin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20261518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261518.